

Dear Lakehouse Investor,

September was another busy month as we held 11 meetings with current and potential portfolio companies, attended one small-cap conference, opened a new position, and provided growth capital to one of the Fund's existing portfolio companies.

The Fund gained 0.6% net of fees and expenses in September compared to a -0.4% fall for the benchmark. Thus far in the first three months of fiscal 2019, the Fund has returned a net 12.0% compared to 1.1% for the benchmark. Since inception in mid-November 2016 the Fund has returned a net 66.0% compared to 32.3% for the benchmark.

Companies Held:	22
Cash Allocation:	12.1%
Top 5 Portfolio Holdings:	37.3%
Net Asset Value per Unit:	\$1.5843
Fund Net Asset Value:	\$180.6 million
Benchmark:	S&P/ASX Small Ordinaries Accumulation Index

The Fund is pacing well towards its objective of long-term outperformance but, as ever, we remind investors that our team does not judge itself based on short-term results and neither should investors who embrace our long-term, high-conviction strategy.

The Fund's most significant contributor to performance during the month was **Pro Medicus** (+22.7%), which we'll discuss in a moment. The most significant detractor, for the second month running, was **BWX** (-15.4%) after the indicative takeover offer was withdrawn. Again, more on that in a moment.

The Fund's five largest holdings as of the end of September accounted for 37.3% of the portfolio and are named in order of the Fund's allocation: **Afterpay Touch**, **Altium**, **Pro Medicus**, **Bapcor** and **Gentrack**. Investors should recognise each of these names as they've been Fund holdings for some time. Collectively, these investments had a good month, which along with the Fund being a net buyer during the month explains why the Fund's cash position decreased from 13.6% to 12.1%.

The Fund's largest sector allocations as of the end of the month were to information technology (69.0% of total capital), health care (10.9%), and consumer discretionary (5.9%), which is quite different to the benchmark's largest allocations: materials (16.9%), consumer discretionary (13.4%), and information technology (10.7%). As ever, we embrace a high active share and do not shy away from leaning into sectors that we think have attractive long-term prospects.

## Impactful Movers

Pro Medicus has been on a run since the release of its full year results in mid-August, up over 43% between results and the end of the month. It's apparent that the Pro Medicus thesis is now better and more widely understood by the market, and while the shares are not conventionally cheap, the business has to date provided us plenty of reasons to stay patient, including: its sticky and highly regarded customer base, high and rising margins, growing pipeline, debt-free balance sheet, high insider ownership, and diverse geographic footprint. Our focus on asymmetric outcomes means we may look to trim if the run continues and the price becomes overly demanding.

BWX was again the Fund's biggest laggard following the proposed buyout by previous management and Bain Capital falling over. This led to the former CEO and CFO formally resigning after an extended leave of absence since the bid was announced in May. It also ended a period of distraction and uncertainty for the company but, on a more positive note, provides some much needed clear air for new management.

While disappointed with how this thesis has played out, BWX is now a much smaller position for the Fund since [selling-down](#) around a [third](#) on announcement of the indicative takeover offer in May. The price has also reset to a level with reduced expectations -- BWX last sold around these levels in February 2016 and only sells on 15 times consensus earnings estimates for fiscal 2019 - that gives us comfort to back the long-view-oriented strategy under new management.

## Wrapping Up

The post-reporting-season period usually welcomes the marketing of new IPO and pre-IPO opportunities. We have already met with a collection of aspiring companies and look forward to meeting with others in the pipeline, alongside seeking out opportunities that are already listed.

As always, thanks to all our investors for your time and trust. It's been a fun ride thus far and, while it's still early days, we're looking forward to celebrating the Fund's second birthday in mid-November. We're honoured to have you with us and look forward to what the future holds.

Best Regards,



**Joe Magyer, CFA**  
Chief Investment Officer

Sole use and confidentiality: This report has been prepared by Lakehouse Capital Pty Limited (ABN 30 614 957 603, authorised representative of AFSL 400691) and by its officers, employees and agents (collectively "Lakehouse") for the sole use of its clients as a record of the performance of

their investment. The contents of this report are confidential, and the client may only disclose such contents to its officers, employees or advisers on a need to know basis, or with the prior written consent of Lakehouse.

**Disclaimer:** The responsible entity for the Lakehouse Small Companies Fund (ARSN 615 265 864) is One Managed Investment Funds Limited (ACN 117 400 987) (AFSL 297042) ("OMIFL"). The information contained in this document was not prepared by OMIFL but prepared by other parties. All of the commentary, statements of opinion and recommendations contain only general advice and have not taken into account your personal circumstances. This report contains general financial product advice only. Any investment in Lakehouse or OMIFL products need to be made in accordance with and after reading the Product Disclosure Statement and Additional Product Disclosure Statement dated 15 November 2016. The opinions, advice, recommendations and other information contained in this report, whether express or implied, are published or made by Lakehouse in good faith in relation to the facts known at the time of preparation. Information is current as at the date of the letter, unless otherwise noted. Past performance is not indicative of future performance.

**Limitation of liability:** Whilst all care has been taken in preparation of this report, to the maximum extent permitted by law, neither Lakehouse or OMIFL will be liable in any way for any loss or damage suffered by you through use or reliance on this information. Lakehouse and OMIFL's liability for negligence, breach of contract or contravention of any law, which cannot be lawfully excluded, is limited, at Lakehouse's option and to the maximum extent permitted by law, to resupplying this information or any part of it to you, or to paying for the resupply of this information or any part of it to you.

**Disclosure:** Lakehouse, its directors, employees and affiliates, may, and likely do, hold units in the Lakehouse Small Companies Fund and securities in entities that are the subject of this report. Copyright: Lakehouse owns the copyright to this publication. Its contents may be used for your own personal use, but you must not (without Lakehouse's consent) alter, reproduce or distribute any part of this publication, transmit it to any other person or incorporate the information into any other document.